Based on the Viridian Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Viridian Therapeutics Inc is USD 39.13 over the next 12 months. Viridian Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Viridian Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Viridian Therapeutics Inc’s stock price was USD 12.02. Viridian Therapeutics Inc’s stock price has changed by +0.25% over the past week, -23.97% over the past month and -24.35% over the last year.
No recent analyst target price found for Viridian Therapeutics Inc
No recent average analyst rating found for Viridian Therapeutics Inc
Company Overview Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Read Less
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the ...Read More
Frequently Asked Questions About Viridian Therapeutics Inc (VRDN) Stock
Based on ratings from 9 analysts Viridian Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on VRDN's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for VRDN is USD 39.13 over the next 12 months. The maximum analyst target price is USD 47 while the minimum anlayst target price is USD 27.
Unfortunately we do not have enough data on VRDN's stock to indicate if its overvalued.
The last closing price of VRDN's stock was USD 12.02.
The most recent market capitalization for VRDN is USD 1.31B.
Based on targets from 9 analysts, the average taret price for VRDN is projected at USD 39.13 over the next 12 months.
This means that VRDN's stock price may go up by +225.57% over the next 12 months.
We can't find any ETFs which contains Viridian Therapeutics Inc's stock.
As per our most recent records Viridian Therapeutics Inc has 143 Employees.
Viridian Therapeutics Inc's registered address is 221 Crescent Street, Waltham, MA, United States, 02453.
You can get more information about it from Viridian Therapeutics Inc's website at https://www.viridiantherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Viridian Therapeutics Inc (VRDN) Stock
Based on ratings from 9 analysts Viridian Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on VRDN's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for VRDN is USD 39.13 over the next 12 months. The maximum analyst target price is USD 47 while the minimum anlayst target price is USD 27.
Unfortunately we do not have enough data on VRDN's stock to indicate if its overvalued.
The last closing price of VRDN's stock was USD 12.02.
The most recent market capitalization for VRDN is USD 1.31B.
Based on targets from 9 analysts, the average taret price for VRDN is projected at USD 39.13 over the next 12 months.
This means that VRDN's stock price may go up by +225.57% over the next 12 months.
We can't find any ETFs which contains Viridian Therapeutics Inc's stock.
As per our most recent records Viridian Therapeutics Inc has 143 Employees.
Viridian Therapeutics Inc's registered address is 221 Crescent Street, Waltham, MA, United States, 02453.
You can get more information about it from Viridian Therapeutics Inc's website at https://www.viridiantherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VRDN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
